ÂÜÀòÂÒÂ×

Katharina Bergerhoff has a strong background in scientific research and development. Katharina currently works at Quell Therapeutics as a Principal Scientist, a position they have held since June 2022. Prior to this, they were a Senior Scientist at the same company from September 2020 to June 2022.

Before joining Quell Therapeutics, Katharina worked at GammaDelta Therapeutics as a Cell therapy and gene engineering Scientist from October 2018 to September 2020, and as a Research Scientist from June 2018 to October 2018.

Katharina also gained valuable experience at The Institute of Cancer Research, where they worked as a Postdoctoral Research Fellow from October 2015 to June 2018. Prior to that, they worked as a PhD student at UCL Cancer Institute from October 2011 to September 2015, focusing on their research in cancer-related fields.

Katharina's additional work experience includes an internship at BONE THERAPEUTICS S.A. in 2010, where they were involved in the preparation and analysis of tissue sections and bone tumor cell lines. Katharina also had an internship at BioGenerix in 2009, where they contributed to the development and validation processes of biosimilars.

Overall, Katharina Bergerhoff has a diverse range of experience in scientific research and development, with a particular focus on cell therapy, gene engineering, and cancer-related fields.

Katharina Bergerhoff's education history began in 2007 when they enrolled at Heidelberg University. Katharina completed their Bachelor of Science (BS) degree in Molecular Biotechnology in 2010. The following year, they pursued their interest in biomedical and molecular sciences research by attending King's College London, where they obtained a Master of Science (MS) degree in 2011. Katharina furthered their studies by pursuing a Doctor of Philosophy (PhD) degree at UCL from 2011 to 2015, specializing in the field of Cancer Immunotherapy.